Ultrasound-Guided Microbubble-Assisted Delivery of Radiopharmaceutical Agents for Gastric Tumor Control.

IF 1.7 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Changyong Zhao, Qiqi Shen, Lei Qin
{"title":"Ultrasound-Guided Microbubble-Assisted Delivery of Radiopharmaceutical Agents for Gastric Tumor Control.","authors":"Changyong Zhao, Qiqi Shen, Lei Qin","doi":"10.1177/10849785261426673","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiopharmaceutical therapy uses drugs with radioactive isotopes for targeted cancer treatment. However, its effectiveness in gastric cancer is often limited by poor tumor penetration, heterogeneous intratumoral distribution, and off-target radiation exposure. Ultrasound-guided microbubble-assisted delivery offers a noninvasive means to increase vascular permeability and enhance tumor-specific radiopharmaceutical uptake.</p><p><strong>Methods: </strong>This study developed and evaluated an ultrasound-guided microbubble delivery system to enhance intratumoral radiopharmaceutical accumulation, therapeutic efficacy, and safety in gastric cancer. Ligand-functionalized, radiopharmaceutical-loaded microbubbles were administered intravenously in an orthotopic gastric tumor model. Tumors were localized by real-time ultrasound imaging and then exposed to focused ultrasound to induce controlled microbubble cavitation. Biodistribution was analyzed using positron emission tomography imaging. Tumor growth was monitored by serial ultrasound, and therapeutic response was assessed with histopathology and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. Radiation safety was determined by organ-specific biodosimetry.</p><p><strong>Results: </strong>Microbubble activation significantly increased intratumoral uptake to 8.4-1.2%ID/g, compared with 3.0 - 0.6%ID/g for conventional delivery (<i>p</i> < 0.001). Tumor-to background ratios improved approximately 2.6-fold, and tumor volumes decreased by 58% relative to controls. Apoptotic indices reached 41.8 - 6.3% in treated tumors versus < 15% in controls; off-target organ uptake remained < 2.0% ID/g.</p><p><strong>Conclusions: </strong>Ultrasound-guided, microbubble-assisted radiopharmaceutical administration increased tumor-specific absorption, slowed tumor development, and decreased systemic exposure, indicating a promising treatment strategy for gastric cancer.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"920-931"},"PeriodicalIF":1.7000,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10849785261426673","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Radiopharmaceutical therapy uses drugs with radioactive isotopes for targeted cancer treatment. However, its effectiveness in gastric cancer is often limited by poor tumor penetration, heterogeneous intratumoral distribution, and off-target radiation exposure. Ultrasound-guided microbubble-assisted delivery offers a noninvasive means to increase vascular permeability and enhance tumor-specific radiopharmaceutical uptake.

Methods: This study developed and evaluated an ultrasound-guided microbubble delivery system to enhance intratumoral radiopharmaceutical accumulation, therapeutic efficacy, and safety in gastric cancer. Ligand-functionalized, radiopharmaceutical-loaded microbubbles were administered intravenously in an orthotopic gastric tumor model. Tumors were localized by real-time ultrasound imaging and then exposed to focused ultrasound to induce controlled microbubble cavitation. Biodistribution was analyzed using positron emission tomography imaging. Tumor growth was monitored by serial ultrasound, and therapeutic response was assessed with histopathology and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays. Radiation safety was determined by organ-specific biodosimetry.

Results: Microbubble activation significantly increased intratumoral uptake to 8.4-1.2%ID/g, compared with 3.0 - 0.6%ID/g for conventional delivery (p < 0.001). Tumor-to background ratios improved approximately 2.6-fold, and tumor volumes decreased by 58% relative to controls. Apoptotic indices reached 41.8 - 6.3% in treated tumors versus < 15% in controls; off-target organ uptake remained < 2.0% ID/g.

Conclusions: Ultrasound-guided, microbubble-assisted radiopharmaceutical administration increased tumor-specific absorption, slowed tumor development, and decreased systemic exposure, indicating a promising treatment strategy for gastric cancer.

超声引导微泡辅助给药控制胃肿瘤的研究。
背景:放射性药物治疗使用含有放射性同位素的药物进行肿瘤靶向治疗。然而,其在胃癌中的有效性往往受到肿瘤穿透性差、肿瘤内分布不均和脱靶辐射暴露的限制。超声引导的微泡辅助输送提供了一种无创的方法来增加血管通透性和增强肿瘤特异性放射性药物的摄取。方法:本研究开发并评估了超声引导微泡给药系统,以增强胃癌肿瘤内放射性药物的蓄积、治疗效果和安全性。在原位胃肿瘤模型中静脉注射配体功能化的载放射性药物微泡。实时超声成像定位肿瘤,聚焦超声诱导可控微泡空化。利用正电子发射断层成像分析生物分布。通过连续超声监测肿瘤生长情况,并通过组织病理学和末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)检测评估治疗效果。辐射安全性采用器官特异性生物剂量法测定。结果:微泡激活显著增加瘤内摄取,达到8.4-1.2%ID/g,而常规给药为3.0 - 0.6%ID/g (p < 0.001)。与对照组相比,肿瘤与背景比值提高了约2.6倍,肿瘤体积减少了58%。治疗组肿瘤细胞凋亡指数达41.8 ~ 6.3%,对照组< 15%;脱靶器官摄取仍< 2.0% ID/g。结论:超声引导、微泡辅助的放射药物给药增加了肿瘤特异性吸收,减缓了肿瘤的发展,减少了全身暴露,是一种很有前景的胃癌治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
2.90%
发文量
87
审稿时长
3 months
期刊介绍: Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书